ORAMED PHARMACEUTICALS INC.
corporate_fare Company Profile
ORAMED PHARMACEUTICALS INC. (NASDAQ:ORMP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 9 items for ORMP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-10, rated 9/10. Across its 9 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for ORMP spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Oramed Q2 2026: $116.5M Net Income Fueled by Alpha Tau Surge, Cash Drops to $15.2M
- Oramed Extends $37.2M Scilex Debt Payment, Faces Stock-for-Cash Risk
- Oramed Reports Strong Q1 Profitability Driven by Investment Gains and Strategic Shift to MedTech Operator Model
- Oramed Pharmaceuticals Completes Strategic Pivot, Divests Oratech and Invests $9M in Lifeward
- Oramed Reports $1.50 EPS from Non-Operating Gain; Operating Loss Hits $15M
Financial Snapshot
Short Interest & Short Volume
7.43 days to coverFINRA reported short interest of 1,307,745 shares in ORMP as of the September 15, 2026 settlement, a 13.3% increase from the prior period — about 7.4 days to cover at its recent average daily volume. On October 2, 2026, 88.5% of ORMP volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.